Carcinogenesis, Teratogenesis & Mutagenesis ›› 2024, Vol. 36 ›› Issue (6): 502-505.doi: 10.3969/j.issn.1004-616x.2024.06.013
Received:2023-12-27
Revised:2024-06-04
Published:2024-12-04
CLC Number:
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
| [1] TORRES-DURÁN M, LOPEZ-CAMPOS J L, BARRECHEGUREN M, et al. Alpha-1 antitrypsin deficiency: outstanding questions and future directions[J]. Orphanet J Rare Dis, 2018, 13(1): 114. [2] LECHOWICZ U, RUDZINSKI S, JEZELA-STANEK A, et al. Post-translational modifications of circulating alpha-1-antitrypsin protein[J]. Int J Mol Sci, 2020, 21(23): 9187. [3] STOCKLEY R A. α1-antitrypsin: a polyfunctional protein?[J]. Lancet Respir Med, 2015, 3(5): 341-343. [4] LOPES A P, MINEIRO M A, COSTA F, et al. Portuguese consensus document for the management of alpha-1-antitrypsin deficiency[J]. Pulmonology, 2018, 24(Suppl 1): 1-21. [5] BAZZAN E, TINè M, BIONDINI D, et al. α1-antitrypsin polymerizes in alveolar macrophages of smokers with and without α1-antitrypsin deficiency[J]. Chest, 2018, 154(3): 607-616. [6] STRNAD P, MCELVANEY N G, LOMAS D A. Alpha1-antitrypsin deficiency[J]. N Engl J Med, 2020, 382(15): 1443-1455. [7] GUTTMAN O, BARANOVSKI B M, SCHUSTER R, et al. Acute-phase protein α1-anti-trypsin: diverting injurious innate and adaptive immune responses from non-authentic threats[J]. Clin Exp Immunol, 2015, 179(2): 161-172. [8] JANCIAUSKIENE S, WRENGER S, IMMENSCHUH S, et al. The multifaceted effects of Alpha1-antitrypsin on neutrophil functions[J]. Front Pharmacol, 2018, 9: 341. [9] 张海燕, 谢世平, 吕顺武, 等. α1-抗胰蛋白酶在艾滋病湿热内蕴证病人血清中的表达及意义[J]. 时珍国医国药, 2019, 30(10): 2532-2533. [10] GERAGHTY P, EDEN E, PILLAI M, et al. α1-Antitrypsin activates protein phosphatase 2A to counter lung inflammatory responses[J]. Am J Respir Crit Care Med, 2014, 190(11): 1229-1242. [11] SAPEY E. Neutrophil modulation in alpha-1 antitrypsin deficiency[J]. Chronic Obstr Pulm Dis, 2020, 7(3): 247-259. [12] EBERT M, JERKE U, EULENBERG-GUSTAVUS C, et al. Protective α1-antitrypsin effects in autoimmune vasculitis are compromised by methionine oxidation[J]. J Clin Invest, 2022, 132(23): e160089. [13] SUN R, XU Z Q, ZHU C X, et al. Alpha-1 antitrypsin in autoimmune diseases: roles and therapeutic prospects[J]. Int Immunopharmacol, 2022, 110: 109001. [14] GREENE C M, MARCINIAK S J, TECKMAN J, et al. α1-Antitrypsin deficiency[J]. Nat Rev Dis Primers, 2016, 2: 16051. [15] CAGNONE M, PILONI D, FERRAROTTI I, et al. A pilot study to investigate the balance between proteases and α1-antitrypsin in bronchoalveolar lavage fluid of lung transplant recipients[J]. High Throughput, 2019, 8(1): 5. [16] STRNAD P, MANDORFER M, CHOUDHURY G, et al. Fazirsiran for liver disease associated with Alpha1-antitrypsin deficiency[J]. N Engl J Med, 2022, 387(6): 514-524. [17] GUYOT N, WARTELLE J, MALLERET L, et al. Unopposed cathepsin G, neutrophil elastase, and proteinase 3 cause severe lung damage and emphysema[J]. Am J Pathol, 2014, 184(8): 2197-2210. [18] JANCIAUSKIENE S, WELTE T. Well-known and less well-known functions of alpha-1 antitrypsin. its role in chronic obstructive pulmonary disease and other disease developments[J]. Ann Am Thorac Soc, 2016, 13(Sup 4): 280-288. [19] AMBADE V N, AMBADE S, GUNDPATIL D B, et al. Biochemical alteration in serum alpha-1 antitrypsin levels in patients with chronic obstructive pulmonary disease[J]. Indian J Clin Biochem, 2024: 1915. [20] HE G H, YU W H, LI H W, et al. Alpha-1 antitrypsin protects against phosgene-induced acute lung injury by activating the ID1-dependent anti-inflammatory response[J]. Eur J Pharmacol, 2023, 957: 176017. [21] POTT G B, CHAN E D, DINARELLO C A, et al. Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood[J]. J Leukoc Biol, 2009, 85(5): 886-895. [22] PARR D G, LARA B. Clinical utility of alpha-1 proteinase inhibitor in the management of adult patients with severe alpha-1 antitrypsin deficiency: a review of the current literature[J]. Drug Des Devel Ther, 2017, 11: 2149-2162. [23] BELCHAMBER K B R, WALKER E M, STOCKLEY R A, et al. Monocytes and macrophages in alpha-1 antitrypsin deficiency[J]. Int J Chron Obstruct Pulmon Dis, 2020, 15: 3183-3192. [24] DE LOYOLA M B, DOS REIS T T A, DE OLIVEIRA G X L M, et al. Alpha-1-antitrypsin: a possible host protective factor against Covid-19[J]. Rev Med Virol, 2021, 31(2): e2157. [25] SUBRAMANIYAM D, STEELE C, K-HNLEIN T, et al. Effects of alpha 1-antitrypsin on endotoxin-induced lung inflammation in vivo[J]. Inflamm Res, 2010, 59(7): 571-578. [26] LIM J H, PARK S M, YOOK J M, et al. Alpha-1 antitrypsin inhibits formaldehyde-induced apoptosis of human peritoneal mesothelial cells[J]. Perit Dial Int, 2020, 40(2): 124-131. [27] LOISON F, ZHU H Y, KARATEPE K, et al. Proteinase 3-dependent caspase-3 cleavage modulates neutrophil death and inflammation[J]. J Clin Invest, 2014, 124(10): 4445-4458. [28] MCELVANEY O F, FRAUGHEN D D, MCELVANEY O J, et al. Alpha-1 antitrypsin deficiency: current therapy and emerging targets[J]. Expert Rev Respir Med, 2023, 17(3): 191-202. [29] FENG Y L, HU L Q, XU Q, et al. Cytoprotective role of alpha-1 antitrypsin in vascular endothelial cell under hypoxia/reoxygenation condition[J]. J Cardiovasc Pharmacol, 2015, 66(1): 96-107. [30] KAHNERT K, J-RRES R A, BEHR J, et al. The diagnosis and treatment of COPD and its comorbidities[J]. Dtsch Arztebl Int, 2023, 120(25): 434-444. [31] LEAP J, ARSHAD O, CHEEMA T, et al. Pathophysiology of copd[J]. Crit Care Nurs Q, 2021, 44(1): 2-8. [32] CHUANG H C, CHEN Y Y, HSIAO T C, et al. Alteration in angiotensin-converting enzyme 2 by PM1 during the development of emphysema in rats[J]. ERJ Open Res, 2020, 6(4): 00174-02020. [33] GOOPTU B, DICKENS J A, LOMAS D A. The molecular and cellular pathology of α1-antitrypsin deficiency[J]. Trends Mol Med, 2014, 20(2): 116-127. [34] HIRAI T. α1-Antitrypsin deficiency[J]. Nihon Rinsho, 2016, 74(5): 869-873. [35] MCELVANEY N G. Diagnosing α1-antitrypsin deficiency: how to improve the current algorithm[J]. Eur Respir Rev, 2015, 24(135): 52-57. [36] BIANCHERA A, ALOMARI E, MICHIELON A, et al. Recombinant alpha-1 antitrypsin as dry powder for pulmonary administration: a formulative proof of concept[J]. Pharmaceutics, 2022, 14(12): 2754. [37] TOPIC A, MILOVANOVIC V, LAZIC Z, et al. Oxidized alpha-1-antitrypsin as a potential biomarker associated with onset and severity of chronic obstructive pulmonary disease in adult population[J]. COPD, 2018, 15(5): 472-478. [38] D'AMATO M, CAMPAGNOLI M, IADAROLA P, et al. Could the oxidation of α1-antitrypsin prevent the binding of human neutrophil elastase in COVID-19 patients?[J]. Int J Mol Sci, 2023, 24(17): 13533. [39] GAO W X, ZHAO J B, KIM H, et al. α1-Antitrypsin inhibits ischemia reperfusion-induced lung injury by reducing inflammatory response and cell death[J]. J Heart Lung Transplant, 2014, 33(3): 309-315. [40] LI Y, KROWKA M J, QI Y W, et al. Alpha1-antitrypsin deficiency carriers, serum alpha 1-antitrypsin concentration, and non-small cell lung cancer survival[J]. J Thorac Oncol, 2011, 6(2): 291-295. [41] SCHWARTZ A G, ROTHROCK M, YANG P, et al. Increased cancer risk among relatives of nonsmoking lung cancer cases[J]. Genet Epidemiol, 1999, 17(1): 1-15. [42] ERCETIN E, RICHTMANN S, DELGADO B M, et al. Clinical significance of SERPINA1 gene and its encoded Alpha1-antitrypsin protein in NSCLC[J]. Cancers, 2019, 11(9): 1306. |
| [1] | SUN Xiaoning, SU Deqi, YANG Haofeng, TIAN Yarong, LIU Hui, HUANG Xiaoxi. Effects of acute exposure to ozone on lung tissue injury in rats [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(3): 219-223. |
| [2] | ZHOU Qinghong, HE Ning, ZHANG Shujing, LIU Hongbo, WEI Jiemin, QIAN Zhiyong. Subacute toxicity of a dietary supplement containing Cyclocarya paliurus and Fagopyrum tataricum in rats [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(2): 133-137. |
| [3] | ZHANG Rui, MA Yuanyuan, HAN Ying, CHONG Xiaomeng, LIU Xinyan, XIE Guangyun, LIANG Yifan, YAO Shangchen, ZHANG Jingpu. Toxicity of ceftriaxone and its impurities to the liver of zebrafish [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 35-41,47. |
| [4] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 66-69,76. |
| [5] | CHEN Shiyi, XIA Zhunan, LIU Xin, YANG Qing. Sub-acute toxicity of ionic liquid 1-heptyl-3-methylimidazolium chloride in mice [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 439-444,451. |
| [6] | LIU Xia, GAO Zibo, DING Lihua, WU Yongjun. Screening of plasma exosome microRNAs in patients with lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(6): 407-412. |
| [7] | TU Yongmei, YU Weihua, PENG Jie, LIU Jiangzheng, LIU Rui, WU Hao, KONG Deqin, HE Gaihua, LI Wenli, WANG Chong. A mechanistic study on irisin-mediated anti-inflammatory and antioxidant effects in cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(4): 247-254,261. |
| [8] | ZHAO Yanjun, YANG Huiying, YI Zhongxun, SUN Huimin, LIN Fei. Inhalation toxicity and safety of impurities CFC115 and HFC1243zf in the pharmaceutical HFA-134a [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(4): 300-306. |
| [9] | HUANG Yali, SUN Huimin, LIN Fei, ZHAO Xia, TANG Long. Biosafety evaluation of 23 pharmaceutical packaging materials by cytotoxicity test [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 139-143. |
| [10] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 75-78,81. |
| [11] | ZHANG Zihan, LI Li, ZHANG Wenfeng, ZHANG Yanchao, CHEN Huiling, SHI Ming. Effects of triphenyl phosphate ontoxicity and phagocytosis of mouse macrophage RAW264.7 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 269-275. |
| [12] | MA Shunpeng, WANG Quankai, WANG Miao, SONG Jiayang, WUHAN Baolier, XIE Guangyun, XU Jianning. Long non-coding RNA regulates apoptosis during glycidyl methacrylate-induced malignant transformation of 16HBE cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 1-5,31. |
| [13] | ZHAO Junwei, HUA Chenfeng, SHANG Pingping, XIE Fuwei, LI Xiang. Induction of oxidative stress by arsenious acid As(Ⅲ) in A549 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 28-31. |
| [14] | LUO Ji, CHEN Xiaoqing, LI Bing, MA Zhongchun. In vitro cytotoxicity evaluation of tongue depressors with different materials [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 58-61,65. |
| [15] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 402-404,408. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
